AU5194598A
(en)
*
|
1996-10-31 |
1998-05-22 |
Human Genome Sciences, Inc. |
(streptococcus pneumoniae) antigens and vaccines
|
US6676943B1
(en)
|
1997-04-24 |
2004-01-13 |
Regents Of The University Of Minnesota |
Human complement C3-degrading protein from Streptococcus pneumoniae
|
US6800744B1
(en)
*
|
1997-07-02 |
2004-10-05 |
Genome Therapeutics Corporation |
Nucleic acid and amino acid sequences relating to Streptococcus pneumoniae for diagnostics and therapeutics
|
US7135560B1
(en)
|
1997-07-02 |
2006-11-14 |
Sanofi Pasteur Limited |
Nucleic acid and amino acid sequences relating to Streptococcus pneumoniae for diagnostics and therapeutics
|
OA11686A
(en)
|
1998-02-20 |
2005-01-12 |
Iaf Biochem Int |
Group B streptococcus antigens.
|
DE69942176D1
(de)
*
|
1998-04-07 |
2010-05-06 |
Medimmune Llc |
Choline-bindende proteine derivate aus pneumokoken als impfstoff
|
PL204863B1
(pl)
|
1998-07-22 |
2010-02-26 |
Stichting Dienst Landbouwkundi |
Zastosowanie mutanta Streptococcus, szczepionka i sposoby kontrolowania lub eliminowania choroby paciorkowcowej w populacji
|
US20030134407A1
(en)
|
1998-07-27 |
2003-07-17 |
Le Page Richard William Falla |
Nucleic acids and proteins from Streptococcus pneumoniae
|
EP1801218A3
(en)
*
|
1998-07-27 |
2007-10-10 |
Sanofi Pasteur Limited |
Nucleic acids and proteins from streptococcus pneumoniae
|
ES2400280T3
(es)
*
|
1998-12-23 |
2013-04-08 |
Id Biomedical Corporation Of Quebec |
Antígenos de estreptococos
|
US7128918B1
(en)
*
|
1998-12-23 |
2006-10-31 |
Id Biomedical Corporation |
Streptococcus antigens
|
EP1950302B1
(en)
|
1998-12-23 |
2012-12-05 |
ID Biomedical Corporation of Quebec |
Streptococcus antigens
|
PT1163000E
(pt)
*
|
1999-03-19 |
2008-03-20 |
Glaxosmithkline Biolog Sa |
Vacina contra antigénios de bactérias
|
US6887480B1
(en)
*
|
1999-06-10 |
2005-05-03 |
Medimmune, Inc. |
Streptococcus pneumoniae proteins and vaccines
|
WO2001096368A2
(en)
*
|
2000-06-14 |
2001-12-20 |
Cytovax Biotechnologies, Inc. |
Use of coiled-coil structural scaffold to generate structure-specific peptides
|
AU7038101A
(en)
*
|
2000-06-20 |
2002-01-02 |
Shire Biochem Inc |
Streptococcus antigens
|
US7074415B2
(en)
*
|
2000-06-20 |
2006-07-11 |
Id Biomedical Corporation |
Streptococcus antigens
|
GB0022742D0
(en)
*
|
2000-09-15 |
2000-11-01 |
Smithkline Beecham Biolog |
Vaccine
|
ATE507238T1
(de)
|
2001-02-02 |
2011-05-15 |
Stichting Dienst Landbouwkundi |
Umwelt-regulierte gene, welche an der virulenz von streptococcus suis beteiligt sind
|
US7262024B2
(en)
|
2001-12-20 |
2007-08-28 |
Id Biomedical Corporation |
Streptococcus antigens
|
US8229903B2
(en)
*
|
2002-12-19 |
2012-07-24 |
International Business Machines Corporation |
Suggesting data interpretations and patterns for updating policy documents
|
CN102526723B
(zh)
|
2005-06-27 |
2017-07-07 |
葛兰素史密丝克莱恩生物有限公司 |
免疫原性组合物
|
EP1754717A1
(en)
|
2005-08-19 |
2007-02-21 |
Université de Lausanne |
Antigenic peptides and their use
|
TWI457133B
(zh)
|
2005-12-13 |
2014-10-21 |
Glaxosmithkline Biolog Sa |
新穎組合物
|
GB0607088D0
(en)
|
2006-04-07 |
2006-05-17 |
Glaxosmithkline Biolog Sa |
Vaccine
|
AR058592A1
(es)
|
2005-12-22 |
2008-02-13 |
Glaxosmithkline Biolog Sa |
Vacuna
|
NZ575273A
(en)
|
2006-09-07 |
2012-02-24 |
Glaxosmithkline Biolog Sa |
Method for making combination vaccine comprising inactivated poliovirus type 1, diptheria toxoid and tetanus toxoid
|
CA2683748C
(en)
|
2007-04-13 |
2016-02-16 |
The Board Of Regents Of The University Of Oklahoma |
Mutants of cholesterol-dependent cytolysins and uses thereof
|
TW200914042A
(en)
|
2007-05-02 |
2009-04-01 |
Glaxosmithkline Biolog Sa |
Vaccine
|
WO2009000825A2
(en)
|
2007-06-26 |
2008-12-31 |
Glaxosmithkline Biologicals S.A. |
Vaccine comprising streptococcus pneumoniae capsular polysaccharide conjugates
|
US20160228500A9
(en)
*
|
2007-07-23 |
2016-08-11 |
Martina Ochs |
Immunogenic Polypeptides and Monoclonal Antibodies
|
EP2183366B1
(en)
*
|
2007-07-23 |
2012-10-24 |
Sanofi Pasteur Limited |
Immunogenic polypeptides and monoclonal antibodies
|
GB0714963D0
(en)
|
2007-08-01 |
2007-09-12 |
Novartis Ag |
Compositions comprising antigens
|
EP2023143A1
(en)
*
|
2007-08-06 |
2009-02-11 |
Boehringer Ingelheim Vetmedica Gmbh |
Immunogenic streptococcus proteins
|
NZ588191A
(en)
|
2008-03-03 |
2012-06-29 |
Irm Llc |
Compounds and compositions as tlr activity modulators
|
EP2612680B1
(en)
*
|
2008-04-16 |
2018-05-23 |
GlaxoSmithKline Biologicals SA |
Vaccine
|
JP5722782B2
(ja)
|
2008-09-26 |
2015-05-27 |
ナノバイオ コーポレーション |
ナノエマルジョン治療用組成物及びその使用方法
|
NZ595291A
(en)
|
2009-03-24 |
2013-08-30 |
Novartis Ag |
Combinations of meningococcal factor h binding protein and pneumococcal saccharide conjugates
|
KR101450958B1
(ko)
|
2009-04-30 |
2014-10-15 |
콜레이 파마시티컬 그룹, 인코포레이티드 |
폐렴구균 백신 및 그의 용도
|
US8668911B2
(en)
|
2009-05-14 |
2014-03-11 |
The Regents Of The University Of Michigan |
Streptococcus vaccine compositions and methods of using the same
|
CN102762226A
(zh)
|
2009-06-10 |
2012-10-31 |
诺华有限公司 |
含苯并萘啶的疫苗
|
TWI445708B
(zh)
|
2009-09-02 |
2014-07-21 |
Irm Llc |
作為tlr活性調節劑之化合物及組合物
|
EP2459216B1
(en)
|
2009-09-02 |
2013-10-30 |
Novartis AG |
Immunogenic compositions including tlr activity modulators
|
DK2473605T3
(en)
|
2009-09-03 |
2018-05-28 |
Pfizer Vaccines Llc |
PCSK9-VACCINE
|
SG178904A1
(en)
|
2009-09-10 |
2012-04-27 |
Novartis Ag |
Combination vaccines against respiratory tract diseases
|
WO2011057148A1
(en)
|
2009-11-05 |
2011-05-12 |
Irm Llc |
Compounds and compositions as tlr-7 activity modulators
|
AU2010339921B2
(en)
|
2009-12-15 |
2016-08-11 |
Glaxosmithkline Biologicals S.A. |
Homogeneous suspension of immunopotentiating compounds and uses thereof
|
WO2011075822A1
(en)
|
2009-12-22 |
2011-06-30 |
Sanofi Pasteur Limited |
Immunogenic compositions and related methods
|
BR112012018343A2
(pt)
*
|
2009-12-22 |
2017-06-27 |
Sanofi Pasteur Ltd |
"composições imunogênicas"
|
GB201003924D0
(en)
|
2010-03-09 |
2010-04-21 |
Glaxosmithkline Biolog Sa |
Immunogenic composition
|
GB201003922D0
(en)
|
2010-03-09 |
2010-04-21 |
Glaxosmithkline Biolog Sa |
Conjugation process
|
GB201003920D0
(en)
*
|
2010-03-09 |
2010-04-21 |
Glaxosmithkline Biolog Sa |
Method of treatment
|
WO2011119759A1
(en)
|
2010-03-23 |
2011-09-29 |
Irm Llc |
Compounds (cystein based lipopeptides) and compositions as tlr2 agonists used for treating infections, inflammations, respiratory diseases etc.
|
WO2012072769A1
(en)
|
2010-12-01 |
2012-06-07 |
Novartis Ag |
Pneumococcal rrgb epitopes and clade combinations
|
AU2011336366B2
(en)
|
2010-12-03 |
2016-05-12 |
Sanofi Pasteur Limited |
Composition for immunization against Streptococcus pneumoniae
|
US20140004142A1
(en)
|
2011-03-02 |
2014-01-02 |
Pfizer Inc. |
Pcsk9 vaccine
|
GB201103836D0
(en)
|
2011-03-07 |
2011-04-20 |
Glaxosmithkline Biolog Sa |
Conjugation process
|
MX339058B
(es)
*
|
2011-05-17 |
2016-05-09 |
Glaxosmithkline Biolog Sa |
Vacuna contra streptococcus pneumoniae.
|
US20150132339A1
(en)
|
2012-03-07 |
2015-05-14 |
Novartis Ag |
Adjuvanted formulations of streptococcus pneumoniae antigens
|
WO2014118305A1
(en)
|
2013-02-01 |
2014-08-07 |
Novartis Ag |
Intradermal delivery of immunological compositions comprising toll-like receptor agonists
|
JP6494527B2
(ja)
|
2013-02-07 |
2019-04-03 |
ザ チルドレンズ メディカル センター コーポレーション |
肺炎球菌のコロニー形成および/または疾患からの保護を提供するタンパク質抗原
|
DK3583947T3
(da)
|
2014-01-21 |
2023-11-06 |
Pfizer |
Streptococcus pneumoniae-kapselpolysaccharider og konjugater deraf
|
US11160855B2
(en)
|
2014-01-21 |
2021-11-02 |
Pfizer Inc. |
Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
|
CN112168957A
(zh)
|
2014-01-21 |
2021-01-05 |
辉瑞大药厂 |
肺炎链球菌荚膜多糖及其缀合物
|
PL3096785T3
(pl)
|
2014-01-21 |
2021-03-08 |
Pfizer Inc. |
Kompozycje immunogenne zawierające skoniugowane antygeny sacharydów otoczkowych i ich zastosowania
|
CA2939416A1
(en)
|
2014-02-14 |
2015-08-20 |
Pfizer Inc. |
Immunogenic glycoprotein conjugates
|
WO2016081839A1
(en)
|
2014-11-21 |
2016-05-26 |
The Board Of Regents Of The University Of Oklahoma |
Pneumolysin mutants and methods of use thereof
|
EP3244917B1
(en)
|
2015-01-15 |
2023-04-19 |
Pfizer Inc. |
Immunogenic compositions for use in pneumococcal vaccines
|
TWI756893B
(zh)
|
2015-07-21 |
2022-03-01 |
美商輝瑞股份有限公司 |
包含經共軛之莢膜糖抗原的致免疫性組成物、包含該致免疫性組成物之套組及彼等之用途
|
GB201518684D0
(en)
|
2015-10-21 |
2015-12-02 |
Glaxosmithkline Biolog Sa |
Vaccine
|
US10786561B2
(en)
|
2015-11-20 |
2020-09-29 |
Pfizer Inc. |
Immunogenic compositions for use in pneumococcal vaccines
|
GB201610599D0
(en)
|
2016-06-17 |
2016-08-03 |
Glaxosmithkline Biologicals Sa |
Immunogenic Composition
|
ES2911490T3
(es)
|
2017-01-20 |
2022-05-19 |
Pfizer |
Composiciones inmunogénicas para su uso en vacunas antineumocócicas
|
MX2020008417A
(es)
|
2018-02-12 |
2020-11-11 |
Inimmune Corp |
Ligandos de receptores de tipo toll.
|
US20210269603A1
(en)
|
2018-07-19 |
2021-09-02 |
Glaxosmithkline Biologicals Sa |
Processes for preparing dried polysaccharides
|
US11260119B2
(en)
|
2018-08-24 |
2022-03-01 |
Pfizer Inc. |
Escherichia coli compositions and methods thereof
|
CA3120922A1
(en)
|
2018-12-12 |
2020-06-18 |
Pfizer Inc. |
Immunogenic multiple hetero-antigen polysaccharide-protein conjugates and uses thereof
|
JP7239509B6
(ja)
|
2019-02-22 |
2023-03-28 |
ファイザー・インク |
細菌多糖類を精製するための方法
|
US20220184199A1
(en)
|
2019-04-10 |
2022-06-16 |
Pfizer Inc. |
Immunogenic compositions comprising conjugated capsular saccharide antigens, kits comprising the same and uses thereof
|
JP2022542316A
(ja)
|
2019-07-31 |
2022-09-30 |
サノフィ パスツール インコーポレイテッド |
多価肺炎球菌多糖体-タンパク質コンジュゲート組成物およびその使用方法
|
MX2022005252A
(es)
|
2019-11-01 |
2022-06-08 |
Pfizer |
Composiciones de escherichia coli y metodos de las mismas.
|
BR112022015796A2
(pt)
|
2020-02-21 |
2022-10-11 |
Pfizer |
Purificação de sacarídeos
|
WO2021165928A2
(en)
|
2020-02-23 |
2021-08-26 |
Pfizer Inc. |
Escherichia coli compositions and methods thereof
|
JP2023546446A
(ja)
|
2020-10-22 |
2023-11-02 |
ファイザー・インク |
細菌多糖を精製する方法
|
WO2022090893A2
(en)
|
2020-10-27 |
2022-05-05 |
Pfizer Inc. |
Escherichia coli compositions and methods thereof
|
JP2023547676A
(ja)
|
2020-11-04 |
2023-11-13 |
エリゴ・バイオサイエンス |
DNAペイロードをアクネ菌集団へとin situ送達するためのファージ由来粒子
|
KR20230097160A
(ko)
|
2020-11-04 |
2023-06-30 |
화이자 인코포레이티드 |
폐렴구균 백신에 사용하기 위한 면역원성 조성물
|
US20220202923A1
(en)
|
2020-12-23 |
2022-06-30 |
Pfizer Inc. |
E. coli fimh mutants and uses thereof
|
WO2022234416A1
(en)
|
2021-05-03 |
2022-11-10 |
Pfizer Inc. |
Vaccination against pneumoccocal and covid-19 infections
|
EP4333879A1
(en)
|
2021-05-03 |
2024-03-13 |
Pfizer Inc. |
Vaccination against bacterial and betacoronavirus infections
|
WO2022249107A2
(en)
|
2021-05-28 |
2022-12-01 |
Pfizer Inc. |
Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
|
EP4346892A2
(en)
|
2021-05-28 |
2024-04-10 |
Pfizer Inc. |
Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
|
WO2023135515A1
(en)
|
2022-01-13 |
2023-07-20 |
Pfizer Inc. |
Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
|
WO2023161817A1
(en)
|
2022-02-25 |
2023-08-31 |
Pfizer Inc. |
Methods for incorporating azido groups in bacterial capsular polysaccharides
|
WO2023218322A1
(en)
|
2022-05-11 |
2023-11-16 |
Pfizer Inc. |
Process for producing of vaccine formulations with preservatives
|